A Comparison of Exenatide and Insulin Glargine

NCT02325960 on ClinicalTrials.gov · last registry update 2017-02-23

Finished July 2016, after enrolling 44 people. Primary outcome, as filed: Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor type: Other
Enrollment: 44
Started: 2015-01
Primary completion: 2016-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.